Login to Your Account

Merck KGaA signs potential $1B deal with F-star

By Randy Osborne
Staff Writer

Monday, June 5, 2017

CHICAGO – Merck KGaA deepened its relationship with F-star Biotechnology Ltd. by way of a new pact to develop and commercialize five bispecific immuno-oncology antibodies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription